Cover Image
市場調查報告書

轉移性激素抗性 (閹割抗性·雄激素非依賴性) 前列腺癌症:全球臨床實驗檢討

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014

出版商 GlobalData 商品編碼 299740
出版日期 內容資訊 英文 177 Pages
訂單完成後即時交付
價格
Back to Top
轉移性激素抗性 (閹割抗性·雄激素非依賴性) 前列腺癌症:全球臨床實驗檢討 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
出版日期: 2014年04月15日 內容資訊: 英文 177 Pages
簡介

本報告提供轉移性的荷爾蒙療法阻力性 (閹割抗性·雄激素非依賴性) 前列腺癌症相關的臨床研究最新趨勢分析,提供疾病·治療方法概要,及主要已開發國家·新興國家的臨床實驗狀況,各地區、各階段、Phase別的進行狀況,彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊,為您概述為以下內容。

目錄

簡介

  • 轉移性激素抗性 (閹割抗性·雄激素非依賴性) 前列腺癌症
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區前五名國家的臨床實驗數量
    • 歐洲前五名國家的臨床實驗數量
    • 北美的主要國家的臨床實驗數量
    • 中東·非洲前五名國家的臨床實驗數量
    • 中南美前五名國家的臨床實驗數量

在G7各國臨床實驗數量:佔腫瘤整體比率

在G7各國臨床實驗數量:各階段(Phase別)

在G7各國臨床實驗數量:各進展狀況

在E7各國臨床實驗數量:佔腫瘤整體比率

在E7各國臨床實驗數量:各階段(Phase別)

在E7各國臨床實驗數量:各進展狀況

各階段(Phase別)臨床實驗數量

  • 進行中的臨床實驗:Phase別

各進展狀況臨床實驗數量

臨床實驗的目標的成就情形

未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商的不同種類的臨床實驗數量

有潛力的贊助商

  • 參加轉移性激素抗性 (閹割抗性·雄激素非依賴性) 前列腺癌症治療藥臨床實驗的前幾名企業

有潛力的藥劑

臨床實驗的最新趨勢(全5件)

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • Johnson & Johnson
    • Sanofi
    • Novartis AG
    • AstraZeneca PLC
    • Astellas Pharma Inc.
    • Medivation, Inc.
    • Dendreon Corporation
    • 武田藥品工業
    • Exelixis, Inc.
    • Bristol-Myers Squibb Company
  • 有代表性的研究機關·醫院臨床實驗概要
    • National Cancer Institute
    • Duke University
    • The University of Texas M. D. Anderson Cancer Center
    • University of California, San Francisco
    • Swiss Group for Clinical Cancer Research
    • Barbara Ann Karmanos Cancer Institute
    • NCIC Clinical Trials Group
    • Memorial Sloan Kettering Cancer Center
    • University of Southern California

5個有代表性的臨床實驗簡介

附錄

圖表一覽

目錄
Product Code: GDHC2087CTIDB

GlobalData's clinical trial report, "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
    • Jan 29, 2014: Preliminary findings from the Phase 2 clinical trial of GTx-758 in men with castration resistant prostate cancer to be presented at ASCO Genitourinary Cancer Symposium
    • Dec 03, 2013: Medivation and Astellas Initiate Phase 3 Study of Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer
    • Dec 02, 2013: Exelixis Initiates Randomized Phase 2 Clinical Trial of Cabozantinib Plus Abiraterone in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
    • Nov 19, 2013: OncoGenex Announces Update on Phase 3 SYNERGY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
    • Sep 26, 2013: Exelixis Announces Full Patient Enrollment Target Has Been Achieved for COMET-1
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Johnson & Johnson
      • Clinical Trial Overview of Johnson & Johnson
      • Sanofi
      • Clinical Trial Overview of Sanofi
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • AstraZeneca PLC
      • Clinical Trial Overview of AstraZeneca PLC
      • Astellas Pharma Inc.
      • Clinical Trial Overview of Astellas Pharma Inc.
      • Medivation, Inc.
      • Clinical Trial Overview of Medivation, Inc.
      • Dendreon Corporation
      • Clinical Trial Overview of Dendreon Corporation
      • Takeda Pharmaceutical Company Limited
      • Clinical Trial Overview of Takeda Pharmaceutical Company Limited
      • Exelixis, Inc.
      • Clinical Trial Overview of Exelixis, Inc.
      • Bristol-Myers Squibb Company
      • Clinical Trial Overview of Bristol-Myers Squibb Company
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • Duke University
      • Clinical Trial Overview of Duke University
      • The University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
      • University of California, San Francisco
      • Clinical Trial Overview of University of California, San Francisco
      • Swiss Group for Clinical Cancer Research
      • Clinical Trial Overview of Swiss Group for Clinical Cancer Research
      • Barbara Ann Karmanos Cancer Institute
      • Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute
      • NCIC Clinical Trials Group
      • Clinical Trial Overview of NCIC Clinical Trials Group
      • Memorial Sloan Kettering Cancer Center
      • Clinical Trial Overview of Memorial Sloan Kettering Cancer Center
      • University of Southern California
      • Clinical Trial Overview of University of Southern California
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Region, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Medivation, Inc., 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Dendreon Corporation, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Exelixis, Inc., 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Swiss Group for Clinical Cancer Research, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by NCIC Clinical Trials Group, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Southern California, 2014*

List of Figures

  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top